Seasoned Executive Brings Wealth of Experience to Leading Ophthalmic Company
Emeryville, CA- April 23, 2014- Santen Inc., the U.S. subsidiary of global ophthalmic pharmaceutical company Santen Pharmaceutical Co., Ltd. (Osaka, Japan) today announced the appointment of Ram Palanki, Pharm.D., as Vice President of Strategic Marketing & Sales. “We are delighted to welcome Ram Palanki to Santen. His Global and US Marketing experience, professional relationships worldwide and in-depth technical expertise in retina will be of tremendous value to Santen," said Dr. Naveed Shams, Chief Science Officer and President & CEO of Santen Inc. “Dr. Palanki brings copious amounts of marketing experience to Santen. His experience and enthusiasm will help us commercialize our compounds which include novel treatments for non-infectious posterior segment uveitis (NI-PSU) and Wet AMD,“ said Dr. Shams.
Dr. Ram Palanki joins Santen with more than a decade of experience in ophthalmology across medical affairs, marketing, sales and reimbursement. Prior to joining Santen, Dr. Palanki was Global Head of Marketing and Sales at Thrombogenics, Inc. and Director of Global Marketing & Sales at Neovista, Inc. He has held positions at Genentech, Inc., where he helped develop and launch Lucentis, at Eyetech Pharmaceuticals, where he was part of the initial team submitting the NDA for Macugen, and at Novartis pharmaceuticals, Inc., in the New Product Commercialization group. Dr. Palanki completed his Post Doctorate fellowship at Rutgers University and obtained his Pharm.D. from Albany College of Pharmacy.
"I am honored to have the opportunity to join a leading ophthalmic company such as Santen," said Ram Palanki, Pharm.D. "Santen has developed a strong pipeline of retina and other products, and I look forward to being part of such a dynamic and innovative team."
ABOUT SANTEN
Santen Pharmaceutical Co., Ltd., is a billion dollar global company headquartered in Osaka, Japan since 1890. With subsidiaries in the U.S., Europe and Asia, Santen researches, develops and markets ophthalmic products for physicians worldwide. Santen’s global product pipeline includes innovative compounds in all stages of clinical development. Among ophthalmic pharmaceutical companies, Santen holds the top share within the Japanese market, is a market leader in China, and is one of the leading ophthalmic companies worldwide. Additional corporate information is available online at www.santeninc.com.